[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11201400145VA - Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide - Google Patents

Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide

Info

Publication number
SG11201400145VA
SG11201400145VA SG11201400145VA SG11201400145VA SG11201400145VA SG 11201400145V A SG11201400145V A SG 11201400145VA SG 11201400145V A SG11201400145V A SG 11201400145VA SG 11201400145V A SG11201400145V A SG 11201400145VA SG 11201400145V A SG11201400145V A SG 11201400145VA
Authority
SG
Singapore
Prior art keywords
ylsulfanyl
indazol
benzamide
pyridin
vinyl
Prior art date
Application number
SG11201400145VA
Inventor
Daniel Scott Gierer
James Eric Morgado
Brendan John Murphy
Daryl Michael Simmons
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201400145VA publication Critical patent/SG11201400145VA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • A61K9/2826Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201400145VA 2011-09-30 2012-09-26 Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide SG11201400145VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541525P 2011-09-30 2011-09-30
PCT/IB2012/055126 WO2013046133A1 (en) 2011-09-30 2012-09-26 Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide

Publications (1)

Publication Number Publication Date
SG11201400145VA true SG11201400145VA (en) 2014-03-28

Family

ID=47116146

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201400145VA SG11201400145VA (en) 2011-09-30 2012-09-26 Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide

Country Status (15)

Country Link
US (1) US20140248347A1 (en)
EP (1) EP2760434A1 (en)
JP (1) JP2013079234A (en)
KR (1) KR20140069297A (en)
CN (1) CN103826618A (en)
AR (1) AR088195A1 (en)
AU (1) AU2012313885A1 (en)
BR (1) BR112014007163A2 (en)
CA (1) CA2847860A1 (en)
IL (1) IL231437A0 (en)
MX (1) MX2014003886A (en)
RU (1) RU2014107767A (en)
SG (1) SG11201400145VA (en)
TW (2) TW201328725A (en)
WO (1) WO2013046133A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8791140B2 (en) 2007-04-05 2014-07-29 Pfizer Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals
BR112014011453A2 (en) 2011-11-11 2017-05-02 Pfizer n-methyl-2- [3 - ((e) -2-pyridin-2-yl-vinyl) -1h-indazol-6-ylsulfanyl] -benzamide for the treatment of chronic myelogenous leukemia
WO2015031604A1 (en) 2013-08-28 2015-03-05 Crown Bioscience, Inc. Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
WO2015067224A1 (en) 2013-11-08 2015-05-14 Zentiva, K.S. Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole
SI3102605T1 (en) 2014-02-04 2019-04-30 Pfizer Inc. Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer
CN104013589A (en) * 2014-05-07 2014-09-03 万特制药(海南)有限公司 Axitinib orally disintegrating tablet and preparation method thereof
WO2016032927A1 (en) 2014-08-25 2016-03-03 Pfizer Inc. Combination of a pd-1 antagonist and an alk inhibitor for treating cancer
CN105769785B (en) * 2014-12-26 2019-02-01 四川科伦药物研究院有限公司 A kind of preparation method of pazopanib tablet
WO2016108106A1 (en) * 2014-12-29 2016-07-07 Shilpa Medicare Limited An improved process for preparation of axitinib
EP4279087A3 (en) 2015-02-26 2024-01-31 Merck Patent GmbH Pd-1 / pd-l1 inhibitors for the treatment of cancer
IL256245B (en) 2015-06-16 2022-09-01 Merck Patent Gmbh Pd-l1 antagonist combination treatments
CN106913547B (en) * 2015-12-28 2021-09-14 山东新时代药业有限公司 Acixtinib tablet and preparation method thereof
KR20190062515A (en) 2016-10-06 2019-06-05 화이자 인코포레이티드 Usage of Abelipab for the Treatment of Cancer
CN106918658B (en) * 2017-01-22 2020-01-31 合肥拓锐生物科技有限公司 axitinib raw materials and analysis method of related substances in preparation thereof
CN109928964B (en) * 2017-12-18 2022-04-15 江苏开元药业有限公司 Synthetic method of axitinib intermediate
WO2019234581A1 (en) * 2018-06-04 2019-12-12 Glenmark Pharmaceuticals Limited Pharmaceutical compositions of axitinib
WO2020003196A1 (en) * 2018-06-28 2020-01-02 Alembic Pharmaceuticals Limited Pharmaceutical composition of axitinib
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
EA202193065A1 (en) * 2019-05-09 2022-03-02 Синтон Б.В. PHARMACEUTICAL COMPOSITION CONTAINING AXITINIB
CN112999176B (en) * 2019-12-19 2022-09-13 鲁南制药集团股份有限公司 Acertinib tablet
CN113943271B (en) * 2020-07-15 2023-11-14 鲁南制药集团股份有限公司 Acetinib crystal form and preparation method thereof
MX2024010773A (en) 2022-03-03 2024-09-10 Pfizer Inc Multispecific antibodies and uses thereof.
EP4282415A1 (en) 2022-05-26 2023-11-29 Genepharm S.A. A stable tablet composition of axitinib

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI262914B (en) 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
WO2004087152A1 (en) 2003-04-03 2004-10-14 Pfizer Inc. Dosage forms comprising ag013736
KR20070058689A (en) 2004-11-02 2007-06-08 화이자 인코포레이티드 Methods for preparing indazole compounds
CN101094836A (en) 2004-11-02 2007-12-26 辉瑞大药厂 Methods for preparing indazole compounds
CA2586177A1 (en) 2004-11-02 2006-05-11 Pfizer Inc. Polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole
CN101052633A (en) 2004-11-02 2007-10-10 辉瑞大药厂 Methods of preparing indazole compounds
MX2007005291A (en) 2004-11-02 2007-07-19 Pfizer Methods of preparing indazole compounds.
CA2608952A1 (en) 2005-05-19 2006-11-23 Dwayne Thomas Friesen Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
US8791140B2 (en) 2007-04-05 2014-07-29 Pfizer Inc. Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyondazole suitable for the treatment of abnormal cell growth in mammals

Also Published As

Publication number Publication date
IL231437A0 (en) 2014-04-30
US20140248347A1 (en) 2014-09-04
CA2847860A1 (en) 2013-04-04
KR20140069297A (en) 2014-06-09
WO2013046133A1 (en) 2013-04-04
JP2013079234A (en) 2013-05-02
AR088195A1 (en) 2014-05-14
RU2014107767A (en) 2015-11-10
AU2012313885A1 (en) 2014-03-13
BR112014007163A2 (en) 2017-04-04
MX2014003886A (en) 2014-05-13
TW201328725A (en) 2013-07-16
CN103826618A (en) 2014-05-28
TW201531309A (en) 2015-08-16
EP2760434A1 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
SG11201400145VA (en) Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
IL276012B (en) Pharmaceutical compositions comprising sorbitan esters
IL230010B (en) Inhalable pharmaceutical compositions
GB201113662D0 (en) Pharmaceutical compositions
ZA201308208B (en) Pharmaceutical compositions
EP2661273A4 (en) Pharmaceutical compositions of iron for oral administration
AP3656A (en) Pharmaceutical compositions
EP2731605A4 (en) Pharmaceutical compositions for rectal administration
HRP20180567T1 (en) Pharmaceutical composition of omeprazole
PL2766008T3 (en) Compositions for nasal application of improved stability
ZA201306734B (en) Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
GB201118181D0 (en) Pharmaceutical compositions
ZA201402166B (en) Compositions of efavirenz
ZA201402165B (en) Compositions of lopinavir
IL229417A0 (en) Pharmaceutical composition comprising fexofenadine
PL2696846T3 (en) Oral pharmaceutical dispersion compositions
EP2727594A4 (en) Novel pharmaceutical composition
EP2714715A4 (en) Pharmaceutical compositions
GB201407689D0 (en) Pharmaceutical compositions of antihypertensives
ZA201205978B (en) Solid pharmaceutical composition for buccal administration of agomelatine
SG11201401570YA (en) Pharmaceutical compositions of resveratrol
GB201105224D0 (en) Novel pharmaceutical compositions
HUP1100561A2 (en) Cocrystals for producing pharmaceutical compositions